This Amendment No. 4 to Schedule 13D (this “Amendment No. 4”) is being filed by Cap 1 LLC, a Delaware limited liability company (“Cap 1”), Richard S. Sackler, M.D. (“Dr. Sackler”), the Richard Sackler Family Foundation, Inc., formerly known as the Richard and Beth Sackler Foundation, Inc. (the “Foundation”), and David Sackler (collectively, the “Reporting Persons” and each, a “Reporting Person”), to amend the Schedule 13D originally filed by the Reporting Persons on September 21, 2016 (the “Original Schedule 13D”), with respect to the beneficial ownership of common stock, $0.01 par value per share (the “Common Stock”), of Peak Resorts, Inc. (the “Company”), a corporation organized under the laws of the State of Missouri. The address of the principal executive offices of the Company is 17409 Hidden Valley Drive, Wildwood, Missouri 63025.
In accordance with Rule 13d-2 of the Act, this Amendment No. 4 amends and supplements, as set forth below, only information in the Original Schedule 13D, as amended and supplemented by Amendment No. 3 to Schedule 13D filed with the SEC on November 21, 2018 (“Amendment No. 3”), and by Amendment No. 2 to Schedule 13D filed with the SEC on August 1, 2017 (“Amendment No. 2”), and by Amendment No. 1 to Schedule 13D filed with the SEC on November 14, 2016 (“Amendment No. 1,” and together with this Amendment No. 4, Amendment No. 3, Amendment No. 2 and the Original Schedule 13D, the “Schedule 13D”), that has materially changed since the filing of Amendment No. 3. All capitalized terms not otherwise defined herein have the meanings ascribed to them in the Schedule 13D.
Item 4. | Purpose of Transaction. |
On July 20, 2019 (the “Signing Date”), the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Vail Holdings, Inc., a Colorado corporation (“Parent”), VRAD Holdings, Inc., a Missouri corporation and direct, wholly-owned subsidiary of Parent (“Merger Sub”), and, solely for the purposes stated in Section 9.14 of the Merger Agreement, Vail Resorts, Inc., a Delaware corporation, relating to the proposed acquisition of the Company by Parent.Pursuant to the terms set forth in the Merger Agreement, Merger Sub will be merged with and into the Company (the “Merger”) with the Company continuing as the surviving corporation in the Merger, and, at the effective time of the Merger (the “Effective Time”): (i) each share of Common Stock issued and outstanding immediately prior to the Effective Time, other than Excluded Shares (as defined in the Merger Agreement), will cease to be outstanding and will be converted into the right to receive $11.00 in cash, without interest (the “Common Merger Consideration”); (ii) each share of the Series A Preferred Stock that is outstanding immediately prior to the Effective Time, other than Excluded Shares, will be converted into the right to receive an amount equal to the sum of: (a) $1,748.81; plus (b) the aggregate amount of all accrued and unpaid dividends on the applicable issuance of Series A Preferred Stock as of the Effective Time, in cash without interest; and (iii) each warrant to purchase shares of Common Stock and that is issued and outstanding immediately prior to the Effective Time will be cancelled with the consent of the holder thereof in exchange for the right to receive an amount in cash, without interest, equal to the product of: (1) the aggregate number of Common Shares (as defined in the Merger Agreement) in respect of such warrant; multiplied by (2) the excess of the Common Merger Consideration over the per share exercise price under such warrant.
The closing of the Merger is subject to, among other conditions, the approval of the Merger Agreement by the affirmative vote of the holders of at least two-thirds of the outstanding shares of Common Stock and Series A Preferred Stock entitled to vote at a special shareholders meeting that will be held on a date to be announced, voting together as a single class on an as-converted basis (the “Company Shareholder Approval”). Consummation of the Merger is not subject to a financing condition.
In addition to the Company Shareholder Approval condition, consummation of the Merger is also subject to various customary closing conditions, and the Company is subject to customary restrictions on its ability to solicit, initiate, facilitate or encourage Alternative Proposals (as defined in the Merger Agreement) from third parties and to provide non-public information to, and participate in discussions and engage in negotiations with, third parties regarding Alternative Proposals, with customary exceptions regarding the Board’s fiduciary duties under applicable law.
Voting and Support Agreements
Concurrently with the execution of the Merger Agreement, Cap 1, Dr. Sackler, the Foundation and David Sackler each entered into a Voting and Support Agreement (each, a “Support Agreement” and, collectively, the “Support Agreements”) with Parent. Pursuant to the Support Agreements, each Reporting Person agreed to, prior to the Expiration Date (as defined below): (i) vote (a) all shares of capital stock of the Company owned, beneficially or of record, by such Reporting Person as of the Signing Date, and (b) all additional shares of capital stock of the Company acquired by the Reporting Person, beneficially or of record, including by way of converting any convertible securities, during the period commencing with the execution and delivery of such Support Agreement and expiring on the Expiration Date, among other things, (1) in favor of the adoption of the Merger Agreement and the approval of the other transactions contemplated thereby (collectively, the “Proposed Transaction”), (2) against the approval or adoption of any Alternative Proposal (as defined in the Merger Agreement) or any other proposal made in opposition to, or in competition with, the Proposed Transaction, and (3) against any Alternative Proposal or any other action that would reasonably be expected to impede, interfere with, delay, postpone, discourage or adversely affect the consummation of the Proposed Transaction; and (ii) not approve any Alternative Transaction (as defined in the Support Agreements) by written consent. In addition to the provisions set forth in the other Support Agreements, the Support Agreement with Cap 1 provides for, among other things, the consent of Cap 1, in its capacity as lender with respect to certain of the Company’s indebtedness, to the Merger.
The Support Agreements will terminate upon the earliest of (the “Expiration Date”): (i) such date and time as the Merger Agreement shall have been validly terminated pursuant to the terms of Article VIII thereof; (ii) the Effective Time; (iii) the date of any amendment, modification or supplement to the Merger Agreement that decreases the amount, or changes the form, of Merger Consideration (as defined in the Merger Agreement) payable to such Reporting Person; (iv) the date upon which Parent and the Reporting Person agree to terminate such Support Agreement in writing; and (v) the date upon which the Company’s board of directors or any committee thereof makes a Company Adverse Recommendation Change (as defined in the Merger Agreement).